Abstracts tagged "Biomarkers"

Abstract Number: 0695 • ACR Convergence 2024
Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort
Stefano Di Donato¹, Marco Minerba², Enrico De Lorenzis³, Collette Hartley⁴, Lesley-Anne Bissell⁵, Rebecca Ross⁶ and Francesco Del Galdo⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Campus Bio-Medico University of Rome, Taranto, United Kingdom, ³Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
Abstract Number: 0838 • ACR Convergence 2024
The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS
Kavya Sugur¹, Emily Chong¹, Srilakshmi Yalavarthi², Katarina Kmetova³, Lyndsay Kluge¹, Wenying Liang², Cyrus Sarosh⁴, NaveenKumar Somanathapura K², Jacqueline Madison², Ajay Tambralli², Jason Knight² and Yu Zuo², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…
Abstract Number: 0964 • ACR Convergence 2024
Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model
Maithri Aspari¹, Voon Ong², Klaus Soendergaard³, Esben Naeser⁴, Malene Hvid⁴, Angela Tam⁵, Shiwen Xu⁵, Christopher Denton⁶, David Abraham⁷, Bent Deleuran¹ and Stinne Greisen⁸, ¹Aarhus University, Aarhus, Denmark, ²University College London, London, England, United Kingdom, ³Aarhus University Hospital, Aarhus, Denmark, ⁴AARHUS UNIVERSITET, AARHUS C, Denmark, ⁵University College London, London, United Kingdom, ⁶University College London, Northwood, United Kingdom, ⁷UCL, London, United Kingdom, ⁸Aarhus University/Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
Abstract Number: 1281 • ACR Convergence 2024
The Brazilian Registry of Juvenile Dermatomyositis: Relationship Between Ultraviolet Radiation and Laboratory Markers of Juvenile Dermatomyositis in a Tropical Country
Beatriz Carneiro¹, Adriana Elias², Claudia Saad-Magalhaes³, Erick Kill², Sylvia Farhat², Teresa Robazzi⁴, Ana Julia Moraes⁵, Sheila Oliveira⁶, Luciana Carvalho⁷, Taciana Fernandes³, Carlos Rabello⁸, Maria Teresa Terreri⁹, Silvana Sacchetti¹⁰, Simone Appenzeller¹¹, Clovis Silva¹², Claudio Len¹³, Darcisio Antonio¹⁴, Iloite Scheibel¹⁵, Melissa Fraga¹⁶, Marcia Bandeira¹⁷, Andre Cavalcante¹⁸, Ana Paula Vecchi¹⁹, Roberto Marini²⁰, Flavio Sztajnbok²¹, Nadia Aikawa²², lucia Maria Campos², Katia Kozu² and Maria Paula Ribeiro², ¹University of São Paulo, São Paulo, SP, Brazil, ²University of Sao Paulo, São Paulo, SP, ³São Paulo State University, Botucatu, ⁴University of Bahia, Salvador, ⁵Para Federal University, Belém do Pará, ⁶Rio de Janeiro Federal University, Rio de Janeiro, Brazil, ⁷University of São Paulo (Ribeirao Preto), Ribeirao Preto, ⁸Albert Sabin Children's Hospital, Fortaleza, ⁹UNIFESP, São Paulo, SP, Brazil, ¹⁰Santa Casa Medical School, São Paulo, SP, Brazil, ¹¹Unicamp, Campinas, SP, Brazil, ¹²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ¹³Federal University of Sao Paulo, São Paulo, SP, ¹⁴São Paulo State University, Botucatu, SP, Brazil, ¹⁵Conceição's Hospital of Porto Alegre, Porto Alegre, ¹⁶Universidade Federal de São Paulo, São Paulo, SP, Brazil, ¹⁷Pequeno Principe Hospital, Curitiba, ¹⁸Pernambuco Federal University, Recife, ¹⁹Children's Hospital of Goiania, Goiânia, ²⁰Campinas State University, Campinas, ²¹UFRJ/UERJ, SAO PAULO, Brazil, ²²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
Background/Purpose: Ultraviolet (UV) waves are risk factors for juvenile dermatomyositis (JDM), when compared to other types of myositis without skin involvement. Patients with JDM have…
Abstract Number: 1553 • ACR Convergence 2024
Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
Torsten Witte¹, Ruth Fernandez Ruiz², Nadezda Abramova³, Dominika Weinelt³, Flavie Moreau⁴, Lena Klopp-Schulze⁵, Jamie Shaw⁶, Deborah Denis⁷ and Joerg Wenzel⁸, ¹Dept of Immunology and Rheumatology, Hannover, Germany, ²Global Clinical Development, EMD Serono, Billerica, MA, ³Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁴Global Biostatistics, EMD Serono, Billerica, MA, ⁵Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, ⁷EMD Serono, Rockland, MA, ⁸Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany
Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…
Abstract Number: 1792 • ACR Convergence 2024
CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus
Lauren Robinson¹, Preetha Balasubramanian², Zurong Wan², Juan Rodriguez Alcazar², Marina Lima Silva Santos², Lynnette Walters³, Jeanine Baisch², Karen Onel⁴, Tracey Wright⁵, Virginia Pascual⁶ and Simone Caielli², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Scottish Rite Hospital for Children, Allen, TX, ⁴HSS, New York, NY, ⁵UT Southwestern, Plano, TX, ⁶Weill Cornell Medical College, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
Abstract Number: 2094 • ACR Convergence 2024
Cross-sectional Associations of Radiographic Multiple Joint Osteoarthritis and Pain with Demographic and Clinical Characteristics: Design of a Multi-modal Study in Human and Pet Dogs
Liubov Arbeeva¹, Kelly Johnson², Serena Savage-Guin³, Tessa Walker², Masataka Enomoto⁴, Christina Stevens⁴, Milja Koskinen⁴, Tracey Cole⁴, Savannah Aker⁴, Connor Thonen-Fleck⁴, Richard Loeser⁵, Jordan Renner², Duncan Lascelles⁶, Yvonne Golightly⁷ and Amanda Nelson⁸, ¹University of North Carolina, Chapel Hill, Carrboro, NC, ²Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill,, Chapel Hill, NC, ⁴Translational Research in Pain and Comparative Pain Research and Education Center, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, ⁵University of North Carolina, Chapel Hill, NC, ⁶North Carolina State University, Raleigh, NC, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Multiple joint osteoarthritis (MJOA) is a progressive, highly prevalent disease affecting millions of Americans and as well as pet dogs. This preliminary analysis sought…
Abstract Number: 2338 • ACR Convergence 2024
TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis
Lenche Kostadinova¹, Brigid Wilson², Hinnah Siddiqui², Sara Behrens³, Angela Gupta⁴, Megan O'Mara³, Vicky Nahra⁵, Mahesha Makandura⁶, Shahdi Malakooti⁷, Maya Mattar⁸, David A Zidar¹ and Donald D Anthony⁹, ¹Louis Stokes VA Medical Center, cleveland, ²VA Northeast Ohio Healthcare System, Cleveland, ³CWRU, Cleveland, ⁴Brigham and Women's Faulkner Hospital, Rheumatology Center, Jamaica Plain, ⁵University Hospitals Cleveland Medical Center, Cleveland, ⁶Henri Ford Medical Center, Detroit, ⁷MetroHealth at Case Western Reserve University, Cleveland, ⁸Louis Stokes VA medical Center, Mayfield Heights, OH, ⁹Louis Stokes VA Medical Center/Metro Health, Cleveland
Background/Purpose: Pathogenic inflammation in psoriatic arthritis (PsA) includes TNF pathway engagement, and this is associated with morbidity. Recently, we observed lower absolute lymphocyte count (ALC)…
Abstract Number: 2536 • ACR Convergence 2024
Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Kevin Bu¹, Rebecca Blank², Adam Cantor¹, Alba Boix-Amoros³, Jose Scher⁴ and Jose Clemente¹, and Accelerating Medicines Partnership and Immune-Mediated Diseases Network (AMP AIM), ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²NYU, New York, NY, ³Icahn School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. Although AIMDs have distinct symptomatology, there is significant overlap in their treatment, suggesting overlap…
Abstract Number: 0109 • ACR Convergence 2024
Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Rohan Willis¹, Anne Tebo², Leslie Skeith³, Nina Kello⁴, H Michael Belmont⁵, Paul Fortin⁶, Guilherme Ramires de Jesús⁷, David Branch⁸, Michelle Petri⁹, Jason Knight¹⁰, Reyhan Kose Cobanoglu¹¹, Maria Laura Bertolaccini¹², Hannah Cohen¹³, Robert Roubey¹⁴, Doruk Erkan¹⁵ and Danieli Andrade¹⁶, and on behalf of APS ACTION, ¹University of Texas Medical Branch, Galveston, TX, ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³University of Calgary, Calgary, ON, Canada, ⁴Northwell Health, Brooklyn, NY, ⁵NYU School of Medicine, New York, NY, ⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ⁸University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁹Johns Hopkins University School of Medicine, Timonium, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, ¹²King's College London, London, United Kingdom, ¹³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶University of São Paulo, São Paulo, SP, Brazil
Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…
Abstract Number: 0463 • ACR Convergence 2024
Evaluation of Inflammatory Indices as Predictive Biomarkers of Carotid Plaque in Patients with Rheumatoid Arthritis
Jose Antonio Davila Jimenez¹, Dionicio Galarza-Delgado², Iris Jazmín Colunga Pedraza³, jose Ramon Azpiri-Lopez⁴, Rosa Icela Arvizu-Rivera³, Jesus Cardenas-de la Garza⁵, Aleydis Gonzalez Melendez³, Andrea Guajardo Aldaco³, Maria F. Elizondo-Benitez⁶, Rebeca L. Polina-Lugo³ and Diego Salcedo-Almanza⁷, ¹Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁷Division of Radiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk compared to the general population. All stages of the atherogenic process appear to…
Abstract Number: 0575 • ACR Convergence 2024
Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA
Kurt de Vlam¹, Pieter Ruytinx², Elien luyten², Anouk Agten², Frank Vandenabeele² and Veerle somers², ¹Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ²Universiteit Hasselt, Hasselt, Belgium
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…
Abstract Number: 0696 • ACR Convergence 2024
MRI DAVIX Index Is an Imaging Biomarker for Endothelial Damage of Systemic Sclerosis Digital Ulcers
Stefano Di Donato¹, Rebecca Ross², Yassir El-Sherbiny³, Riccardo Bixio⁴, Marco Minerba⁵, Christopher Wasson⁶, Jun Li⁷, Jochen SCHMITZ⁸, Sudha Visvanathan⁹ and Francesco Del Galdo⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³Nottingham Trent University, Nottingham, United Kingdom, ⁴University of Verona, Verona, Verona, Italy, ⁵1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom, ⁷Boehringer Ingelheim, Danbury, CT, ⁸Boehringer-Ingelheim, Ridgefield, CT, ⁹Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT
Background/Purpose: Circulating endothelial cells (CEC) and their precursors have been shown to correlate to the severity of vascular manifestations in Systemic sclerosis1, such as Digital…
Abstract Number: 0849 • ACR Convergence 2024
Effectiveness of Tocilizumab in Aortitis and Aneurysms Associated with Giant Cell Arteritis. Multicenter Open-label Study
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Iñigo Hernández-Rodríguez⁴, Susana Romero Yuste⁵, Eugenio De Miguel⁶, Eva Galindez-Agirregoikoa⁷, ivan Ferraz-Amaro⁸, Julio Sánchez-Martín⁹, Patricia Moya Albarado¹⁰, Cristina Campos Fernández¹¹, Fernando Lopez-Gutierrez¹², Santos Castañeda¹³ and Ricardo Blanco-Alonso¹⁴, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁵Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Hospital de San Pau, Barcelona, Spain, ¹¹Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant Cell Arteritis (GCA) was initially described involving mainly the extracranial branches of the carotid arteries. However, GCA also may involve the aorta (GCA-aortitis)…
Abstract Number: 1090 • ACR Convergence 2024
Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy
Naomi Schlesinger¹, Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux³ and Peter Lipsky⁴, ¹University of Utah, Salt Lake City, UT, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Inc., Deerfield, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD),1 with elevated serum urate (SU) and high flare frequency (≥3 flares/yr) contributing.2 The Fib-4 index, calculated from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].